Equity analysts have recently weighed in with favorable reports on Repros Therapeutics Inc (NASDAQ:RPRX), as the company’s Androxal AdCom meeting and PDUFA preparations are in high …
Brean Capital analyst Jonathan Aschoff is out today with his second note this week on Repros Therapeutics (NASDAQ:RPRX) maintaining a Buy rating, with a $41 price target, following …
In a research report published Monday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price target, which …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a price target …
In a research report published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price target. …
